Derivatives of cephalosporin for treating cancer

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10821114
APP PUB NO 20170119784A1
SERIAL NO

15301462

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to a new class of cephalosporin derivatives of formula (I), notably having CXCR4 receptor antagonist effect, useful as a therapeutic agent for treating cancer, in particular for treating breast cancer, lung cancer and uveal melanoma. The invention further relates to a pharmaceutical composition comprising a compound of formula (I) and an additional antitumor drug for treating cancer.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
INSTITUT CURIE75248 PARIS CEDEX 05
HARMONIC PHARMA54500 VANDOEUVRE LES NANCY

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Decaudin, Didier Paris, FR 12 79
Karaboga, Arnaud Sinan Schiltigheim, FR 2 0
Perez-Nueno, Violeta Isabel Viladecans-Barcelona, ES 1 0
Souchet, Michel Gif sur Yvette, FR 2 0

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 May 3, 2028
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 3, 2032
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00